Navigation Links
Molecular Detection Inc. Launches Improved Version of Detect-Ready® MRSA Panel at 2012 ECCMID Congress

LONDON and WAYNE, Pa., March 30, 2012 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced it will release a new version of its Detect-Ready MRSA Panel at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).  The superior performance of the Detect-Ready MRSA Panel has been further enhanced by increasing the number of MRSA strains it can detect, adding MRSA strains known to be missed by at least one other market-leading assay to the universe of all known common MRSA strains that were already included.  The new kit also shortens the sample preparation process and minimizes required "hands-on" time.

The Detect-Ready MRSA Panel is a qualitative real-time PCR in vitro diagnostic test.  It is CE-marked for the detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive S. aureus) and is the only marketed PCR-based MRSA screening test with the proven ability to discriminate accurately between these pathogens and other related bacteria. 

"We are delighted to offer this improved version of the Detect-Ready MRSA Panel to our growing customer base," commented David Wilson, MDI's Vice President for Commercial Operations, Europe.  "The inclusion of additional covered MRSA strains reinforces the superior performance of our existing test, which was recently reconfirmed in an independent comparative study with a market leading competitor.  In addition, the simplicity and ease-of-use of Detect-Ready MRSA is further enhanced with our new streamlined protocol for sample prep." 

Comparative data confirming the greater accuracy of the Detect-Ready MRSA panel was generated by researchers at St. Thomas' Hospital in London as part of an academic study.  The study compared the performance of MDI's test and the Becton Dickinson GeneOhm MRSA PCR sold by BD Diagnostics.  The researchers concluded that the Detect-Ready MRSA assay is superior to the GeneOhm panel in terms of specificity, while still providing a more rapid screening service compared to traditional microbiology culture methods.*

Detect-Ready kits are compatible with a number of the real time-PCR platforms currently found in most hospitals.  Samples for testing are simple to obtain using nasal swabs and the kit's ready-to-use pre-mixed reagents require only the addition of patient sample to run the test, which provides results in less than three hours.  Unlike other tests that require special handling, Detect-Ready kits are off-the-shelf room temperature-stabilized and require no refrigeration. 

The Detect-Ready MRSA Panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, the Netherlands, Belgium, Luxembourg, Australia and Israel, and is in late-stage development in the US.

To learn more about the Detect-Ready MRSA Panel at ECCMID, visit Launch Diagnostics, MDI's distributor for the UK, France and Ireland, at Booth 577, or Alere, MDI's distributor for Germany, Austria and Switzerland, at Booth 615, or visit

The 22nd European Congress of Clinical Microbiology and Infectious Diseases will be held in London, UK from March 31 to April 3, 2012.  For more information, visit

* A Comparative Study of Two MRSA PCR Assays, Sarah L. White, Eugene P. Halligan, Penelope R. Cliff Infection Sciences, GSTS Pathology, St. Thomas' Hospital, London, UK, 2011.

About Molecular Detection
Molecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing a portfolio of sample-to-answer Detect-Ready® molecular diagnostic tests for the detection of infectious diseases.  The company's first product, a ready-to-use, rapid detection panel for hospital-based MRSA screening, is currently commercially available in the EU, Australia and the Middle East. The Detect-Ready MRSA Panel provides increased accuracy, faster time to results and more efficient utilization of hospital resources compared to other MRSA diagnostic products.  MDI's real-time PCR tests are based on novel patented technologies for differential diagnosis and room-temperature stabilization.  For more information, visit Molecular Detection Inc.:

Media: David Wilson

Barbara Lindheim VP Commercial Operations, Europe

GendeLLindheim BioCom Partners+44 (0) 7806 933 659

+1 (212) 584-2276 x2 



SOURCE Molecular Detection Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
2. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
5. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
10. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
11. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
Post Your Comments:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):